CA
NZ
UK
AU
IND
US
…
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Nyrada Inc is an Australian clinical-stage biotechnology company developing small-molecule therapeutics for cardiovascular and neurological disorders. Its long-term growth may be driven by successful progression of development programs, favourable clinical outcomes and potential licensing or commercialization deals addressing significant unmet medical needs. Investors may find the company attractive for milestone-driven upside tied to pipeline advancement in large therapeutic areas.
Principal investment risks include high clinical and regulatory risk, the likely need for additional funding with potential equity dilution, limited revenue history and intense competition in cardiovascular and neurological therapeutics.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -8.53M | -4.85M | -4.60M | -7.78M | -3.96M |
| Net income | -6.53M | -4.85M | -1.39M | -7.78M | -3.96M |
| Selling general administrative | 5.06M | 1.44M | 1.06M | 2.28M | 2.67M |
| Selling and marketing expenses | - | 1.40M | 1.49M | - | - |
| Gross profit | -0.00M | -1.98M | -0.81M | - | - |
| Reconciled depreciation | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M |
| Ebit | -8.57M | -5.01M | -4.60M | -9.36M | -3.96M |
| Ebitda | -8.57M | -5.00M | -4.60M | -9.35M | -3.95M |
| Depreciation and amortization | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M |
| Operating income | -8.57M | -9.20M | -4.56M | -9.36M | -3.96M |
| Other operating expenses | 8.57M | 11.60M | 6.60M | 9.36M | 5.07M |
| Interest expense | - | - | - | - | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.18M | 0.16M | 0.16M | 0.15M | 0.01M |
| Net interest income | 0.18M | 0.16M | 0.16M | 0.15M | 0.01M |
| Income tax expense | -2.00M | -2.40M | -3.22M | -0.15M | 0.00M |
| Total revenue | - | 2.40M | 3.24M | 1.58M | 1.11M |
| Total operating expenses | 8.57M | 7.22M | 4.56M | 9.36M | 5.07M |
| Cost of revenue | 0.00M | 4.38M | 2.03M | - | - |
| Total other income expense net | 0.04M | 4.36M | -0.04M | 1.43M | -0.00M |
| Net income from continuing ops | -6.56M | -4.85M | -1.39M | -7.78M | -3.96M |
| Net income applicable to common shares | - | -4.85M | -1.39M | -7.78M | -3.96M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 10.42M | 5.30M | 5.91M | 5.16M | 12.01M |
| Intangible assets | 0.03M | 0.03M | - | 0.03M | 0.04M |
| Other current assets | 0.20M | - | 0.08M | - | 0.08M |
| Total liab | 0.88M | 1.72M | 0.86M | 0.91M | 0.52M |
| Total stockholder equity | 9.54M | 3.58M | 5.05M | 4.26M | 11.50M |
| Other current liab | 0.68M | - | 0.72M | 0.38M | 0.41M |
| Common stock | 40.03M | - | 26.84M | 25.32M | 25.32M |
| Capital stock | 40.03M | 29.77M | - | 25.32M | 25.32M |
| Retained earnings | -35.29M | -29.58M | -27.19M | -27.22M | -19.52M |
| Other liab | - | - | - | 0.02M | 0.04M |
| Cash | 8.38M | 2.93M | 4.77M | 3.71M | 10.82M |
| Cash and equivalents | - | - | - | - | 10.82M |
| Total current liabilities | 0.87M | 1.72M | 0.84M | 0.88M | 0.47M |
| Net debt | -8.38M | - | -4.77M | -3.71M | -10.82M |
| Short term debt | - | - | - | - | 0.00M |
| Other stockholder equity | - | - | - | 6.15M | 5.69M |
| Property plant equipment | - | - | - | 0.00M | 0.01M |
| Total current assets | 10.38M | 5.27M | 5.87M | 5.13M | 11.97M |
| Net tangible assets | - | - | - | 4.22M | 11.46M |
| Net receivables | 1.80M | 2.16M | 1.02M | 1.42M | 1.07M |
| Accounts payable | 0.19M | 0.91M | 0.12M | 0.51M | 0.07M |
| Accumulated other comprehensive income | 4.80M | - | 5.40M | 6.15M | 5.69M |
| Non currrent assets other | - | - | 0.03M | - | - |
| Non current assets total | 0.04M | 0.03M | 0.03M | 0.04M | 0.04M |
| Long term debt total | - | - | - | - | 0.00M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | 0.00M | 0.00M | - | -0.00M |
| Change to liabilities | - | - | - | 0.25M | -0.20M |
| Total cashflows from investing activities | -0.01M | 0.00M | 0.00M | 0.00M | -0.00M |
| Total cash from financing activities | 9.96M | 3.19M | 1.83M | 0.00M | -0.27M |
| Change to operating activities | - | - | - | 0.05M | 0.06M |
| Net income | -6.53M | -4.85M | -1.39M | -7.78M | -3.96M |
| Change in cash | 5.45M | -1.84M | 1.06M | -7.11M | -2.93M |
| Begin period cash flow | 2.93M | 4.77M | 3.71M | 10.82M | 13.75M |
| End period cash flow | 8.38M | 2.93M | 4.77M | 3.71M | 10.82M |
| Total cash from operating activities | -4.49M | -5.05M | -0.77M | -7.20M | -3.96M |
| Issuance of capital stock | 10.41M | 3.45M | 1.97M | - | - |
| Depreciation | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M |
| Other cashflows from investing activities | - | 0.00M | 0.00M | - | - |
| Change to account receivables | 0.34M | -1.24M | 0.31M | -0.26M | 0.21M |
| Sale purchase of stock | -0.41M | -0.25M | -0.14M | - | -0.22M |
| Other cashflows from financing activities | - | 3.19M | 0.01M | 0.00M | -0.04M |
| Change to netincome | - | - | - | 0.54M | 0.97M |
| Capital expenditures | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.48M | -1.19M | 0.26M | 1.32M | 1.37M |
| Stock based compensation | - | 0.18M | - | - | - |
| Other non cash items | 2.51M | 0.80M | 0.36M | - | 3.96M |
| Free cash flow | -4.50M | -5.05M | -0.77M | -7.20M | -3.96M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NYR Nyrada Inc |
0.05 11.24% |
0.49 | - | - | 63.95 | 13.21 | -2.17 |
| CSL CSL Ltd |
-0.36 0.18% |
202.04 | - | 22.57 | 6.15 | 4.48 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.41 2.91% |
13.67 | 93.87 | 166.67 | 5.37 | 6.37 | 47.29 |
| NEU Neuren Pharmaceuticals Ltd |
- -% |
23.24 | 154.93 | 36.36 | 42.38 | 7.52 | 160.40 |
| MSB Mesoblast Ltd |
-0.14 6.45% |
2.03 | - | 454.55 | 23.43 | 3.36 | -9.86 |
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia. Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. James Bonnar | Chief Exec. Officer | NA |
| Mr. Cameron Jones C.A. | Chief Financial Officer | NA |
| Mr. Benjamin Evison Ph.D. | Chief Scientific Officer | NA |
| Ms. Laura Vize | Investor Relations Mang. | NA |
| Mr. Mark Waring B.Sc., P.M.P. | Sr. VP of US Operations | NA |
| Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. | Company Sec. | 1970 |
| Mr. James Bonnar | Chief Executive Officer | NA |
| Mr. Dimitri Burshtein | Investor Relations Manager | NA |
| Mr. Mark Waring B.Sc., P.M.P. | Senior Vice President of US Operations | NA |
| Mr. David James Franks BEc, C.A., F Fin, J.P. | Company Secretary | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...